Prazosin Group D

1. PrazosinGroup D E. N. K. M. D. C. J. S. L. Y.

2. Assessment • Palpation of lower abdomen for distention • Evaluate previous patterns of voiding • Evaluate time intervals between voiding • Monitor intake and outtake • Monitor BUN & Creatinine

3. Diagnosis • Urinary retention related to urethral blockage as evidence by frequent urination • At risk for deficient fluid balance • Acute pain

4. Planning Goal: Void in sufficient amounts with no palpable bladder distention Outcome: demonstrate post void residuals of less than 50mL, with absence of dribbling/ or overflows

5. Implementation • Encourage patient to void every 2 hours when the urge is present • Observe urinary stream, noting size and force • Encourage fluids up to 3000mL daily, within cardiac tolerance • Percuss/ palpate suprapubic area • Catherize for residual urine and leave indwelling catheter as indicated • Patient given Prazosin

6. Evaluation • Voiding in sufficient amounts with no palpable bladder distention • Demonstrates post void residuals of less than 50 mL with absence of dribbling and over flow

7. Prazosin • Drug given off label to treat benign prostatic hypertrophy MOA • dilates both arteries and veins by blocking postsynaptic alpha1- adrenergic receptors • Decreases contractions in smooth muscle of prostatic capsule

8. Nursing Responsibilities • Advise pt to weigh self twice weekly and assess feet and ankles for fluid retention • Advise pt drug may cause dizziness & drowsiness • Advise pt to avoid sudden changes in position to decrease orthostatic hypotension • Advise pt to report swelling of feet and lower legs, dizziness and fainting if it occurs frequently